Home » Sticking Points in Compounding Talks Reflect Long-Held FDA Frustrations
Sticking Points in Compounding Talks Reflect Long-Held FDA Frustrations
House and Senate aides negotiating compounding pharmacy legislation are quibbling over what volume of interstate commerce by compounders should trigger mandatory FDA oversight, and how that volume should be measured. The differences negotiators are trying to bridge address the same ambiguities that make FDA enforcement so difficult under current law, sources close to the negotiations said Monday.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May